People taking a popular diabetes medication called semaglutide, sold under brand names like Ozempic, Wegovy, and Rybelsus may face a small but important risk to their vision, according to new research ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

Rybelsus ® reduced major adverse cardiovascular ... in participants with and without concomitant SGLT2i use during trial 7. SOUL confirmed the well-established safety and tolerability profile ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults with type 2 diabetes. A regulatory decision is anticipated in 2025.

The pill also slashed the risk of non-fatal strokes by 12% and cardiovascular-related death by 7% compared to placebo. There was no significant difference between the Rybelsus and placebo groups ...